A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer

Hei Cheul Jeung, SunYoung Rha, Sung Hoon Noh, Jae Kyung Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: This study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients. Methods: Patients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria. Results: Forty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9-39.3%) and disease control rate was 63.8% (95% CI, 50.9-79.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3-4 were rare with occurrence rate of 14.9% for anorexia and emesis. Conclusions: Fractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume59
Issue number3
DOIs
Publication statusPublished - 2007 Mar 1

Fingerprint

irinotecan
Chemotherapy
Cisplatin
Stomach Neoplasms
Toxicity
Drug Therapy
Disease control
Salvaging
Taxoids
Anorexia
Combination Drug Therapy
Neutropenia
Vomiting
Disease Progression
Stomach
Appointments and Schedules
Adenocarcinoma
Therapeutics
Survival Rate
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

@article{08de91ea3ba24a70be7bdd3792070d3a,
title = "A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer",
abstract = "Purpose: This study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients. Methods: Patients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria. Results: Forty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5{\%} (95{\%} CI, 12.9-39.3{\%}) and disease control rate was 63.8{\%} (95{\%} CI, 50.9-79.5{\%}) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6{\%}. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3-4 were rare with occurrence rate of 14.9{\%} for anorexia and emesis. Conclusions: Fractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.",
author = "Jeung, {Hei Cheul} and SunYoung Rha and Noh, {Sung Hoon} and Roh, {Jae Kyung} and Hyuncheol Chung",
year = "2007",
month = "3",
day = "1",
doi = "10.1007/s00280-006-0272-z",
language = "English",
volume = "59",
pages = "313--320",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. / Jeung, Hei Cheul; Rha, SunYoung; Noh, Sung Hoon; Roh, Jae Kyung; Chung, Hyuncheol.

In: Cancer Chemotherapy and Pharmacology, Vol. 59, No. 3, 01.03.2007, p. 313-320.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer

AU - Jeung, Hei Cheul

AU - Rha, SunYoung

AU - Noh, Sung Hoon

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Purpose: This study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients. Methods: Patients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria. Results: Forty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9-39.3%) and disease control rate was 63.8% (95% CI, 50.9-79.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3-4 were rare with occurrence rate of 14.9% for anorexia and emesis. Conclusions: Fractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.

AB - Purpose: This study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients. Methods: Patients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria. Results: Forty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9-39.3%) and disease control rate was 63.8% (95% CI, 50.9-79.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3-4 were rare with occurrence rate of 14.9% for anorexia and emesis. Conclusions: Fractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.

UR - http://www.scopus.com/inward/record.url?scp=33845887710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845887710&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0272-z

DO - 10.1007/s00280-006-0272-z

M3 - Article

C2 - 16770582

AN - SCOPUS:33845887710

VL - 59

SP - 313

EP - 320

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -